Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro

World Journal of Gastroenterology

Volumn 16, Issue 16, 2010, Pages 2028-2037

  Xu, Wen Sheng ^a   Zhao, Ke Kai ^b   Miao, Xiao Hui ^a   Ni, Wu ^a   Cai, Xiong ^a   Zhang, Rui Qi ^a   Wang, Jun Xue ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b No 404 Hospital of PLA   (China)

Author keywords

Covalently closed circular DNA; Hepatitis B virus; Oxymatrine; Pregenomic RNA; Replication intermediates

Indexed keywords

COVALENTLY CLOSED CIRCULAR DNA; DNA POLYMERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; OXYMATRINE; PREGENOMIC RNA; RELAXED CIRCULAR DNA; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

EID: 77951969449     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i16.2028     Document Type: Article

References (47)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745
2. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-861
3. Peters M. Mechanisms of action of interferons. Semin Liver Dis 1989; 9: 235-239
4. Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res 1999; 19: 817-828
5. Taylor JL, Grossberg SE. The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol 1998; 25: 23-29
6. Wang BE. Treatment of chronic liver diseases with traditional Chinese medicine. J Gastroenterol Hepatol 2000; 15 Suppl: E67-E70
7. Liu J, Zhu M, Shi R, Yang M. Radix Sophorae flavescentis for chronic hepatitis B: a systematic review of randomized trials. Am J Chin Med 2003; 31: 337-354
8. Lai JP, He XW, Jiang Y, Chen F. Preparative separation and determination of matrine from the Chinese medicinal plant Sophora flavescens Ait by molecularly imprinted solidphase extraction. Anal Bioanal Chem 2003; 375: 264-269
9. Lin M, Yang LY, Li WY, Peng YP, Zheng JK. Inhibition of the replication of hepatitis B virus in vitro by oxymatrine. J Int Med Res 2009; 37: 1411-1419.
10. Chen XS, Wang GJ, Cai X, Yu HY, Hu YP. Inhibition of hepatitis B virus by oxymatrine in vivo. World J Gastroenterol 2001; 7: 49-52.
11. Lu LG, Zeng MD, Mao YM, Li JQ, Wan MB, Li CZ, Chen CW, Fu QC, Wang JY, She WM, Cai X, Ye J, Zhou XQ, Wang H, Wu SM, Tang MF, Zhu JS, Chen WX, Zhang HQ. Oxymatrine therapy for chronic hepatitis B: a randomized doubleblind and placebo-controlled multi-center trial. World J Gas troenterol 2003; 9: 2480-2483.
12. Yang W, Zeng M, Fan Z, Mao Y, Song Y, Jia Y, Lu L, Chen CW, Peng YS, Zhu HY. [Prophylactic and therapeutic effect of oxymatrine on D-galactosamine-induced rat liver fibrosis] Zhonghua Ganzangbing Zazhi 2002; 10: 193-196.
13. Xiang X, Wang G, Cai X, Li Y. Effect of oxymatrine on murine fulminant hepatitis and hepatocyte apoptosis. Chin Med J (Engl) 2002; 115: 593-596.
14. Mao YM, Zeng MD, Lu LG, Wan MB, Li CZ, Chen CW, Fu QC, Wang JY, She WM, Cai X, Ye J, Zhou XQ, Wang H, Wu SM, Tang MF, Zhu JS, Chen WX, Zhang HQ. Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study. World J Gastroenterol 2004; 10: 3269-3273.
15. [The guidelines of prevention and treatment for chronic hepatitis B] Zhonghua Ganzangbing Zazhi 2005; 13: 881-891.
16. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-415.
17. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
18. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987; 84: 1005-1009.
19. Li CQ, Zhu YT, Zhang FX, Fu LC, Li XH, Cheng Y, Li XY. Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo. World J Gastroenterol 2005; 11: 426-428
20. Köck J, Schlicht HJ. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J Virol 1993; 67: 4867-4874
21. Singh M, Dicaire A, Wakil AE, Luscombe C, Sacks SL. Quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the liver of HBV-infected patients by LightCycler real-time PCR. J Virol Methods 2004; 118: 159-167
22. Pugh JC, Yaginuma K, Koike K, Summers J. Duck hepatitis B virus (DHBV) particles produced by transient expression of DHBV DNA in a human hepatoma cell line are infectious in vitro. J Virol 1988; 62: 3513-3516
23. Hu JM, Seeger C. RNA Signals That Control DNA Replication in Hepadnaviruses. Semin Virol 1997; 8: 205-211
24. Cao F, Tavis JE. Suppression of mRNA accumulation by the duck hepatitis B virus reverse transcriptase. Virology 2006; 350: 475-483
25. Hsiao LL, Dangond F, Yoshida T, Hong R, Jensen RV, Misra J, Dillon W, Lee KF, Clark KE, Haverty P, Weng Z, Mutter GL, Frosch MP, MacDonald ME, Milford EL, Crum CP, Bueno R, Pratt RE, Mahadevappa M, Warrington JA, Stephanopoulos G, Stephanopoulos G, Gullans SR. A compendium of gene expression in normal human tissues. Physiol Genom ics 2001; 7: 97-104
26. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27: 493-497
27. Sells MA, Zelent AZ, Shvartsman M, Acs G. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol 1988; 62: 2836-2844
28. Acs G, Sells MA, Purcell RH, Price P, Engle R, Shapiro M, Popper H. Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. Proc Natl Acad Sci USA 1987; 84: 4641-4644
29. Cheng Y, Ping J, Xu HD, Fu HJ, Zhou ZH. Synergistic effect of a novel oxymatrine-baicalin combination against hepatitis B virus replication, alpha smooth muscle actin expression and type I collagen synthesis in vitro. World J Gastroenterol 2006; 12: 5153-5159
30. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129
31. Magnius LO, Espmark JA. New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol 1972; 109: 1017-1021
32. Abdelhamed AM, Kelley CM, Miller TG, Furman PA, Cable EE, Isom HC. Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay. Antimi crob Agents Chemother 2003; 47: 324-336
33. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE 4th, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758
34. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006; 11: 909-916
35. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684
36. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-308
37. Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, Leung NW, Locarnini S, Chan HL. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-1897
38. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirusinfected cells. Cell 1986; 47: 451-460
39. Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990; 175: 255-261
40. Borel C, Schorr O, Durand I, Zoulim F, Kay A, Trepo C, Hantz O. Initial amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of embryonic duck hepatocytes is increased by cell cycle progression. Hepatology 2001; 34: 168-179
41. Murray JM, Wieland SF, Purcell RH, Chisari FV. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci USA 2005; 102: 17780-17785
42. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736-1742
43. Yang W, Mason WS, Summers J. Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus-infected liver. J Virol 1996; 70: 4567-4575
44. Birnboim HC, Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res 1979; 7: 1513-1523
45. Jeong JH, Kwak DS, Rho HM, Jung G. The catalytic properties of human hepatitis B virus polymerase. Biochem Bio phys Res Commun 1996; 223: 264-271
46. Julander JG, Sidwell RW, Morrey JD. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res 2002; 55: 27-40
47. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2', 3' -dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 8495-8499